Back to top
more

Ayr Wellness Inc. (AYRWF)

(Delayed Data from OTC)

$1.89 USD

1.89
66,156

+0.07 (3.85%)

Updated Oct 14, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (73 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

InMode (INMD) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

InMode (INMD) delivered earnings and revenue surprises of 2.86% and 0.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Ayr Wellness Inc. (AYRWF) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Ayr Wellness Inc. (AYRWF), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Fast-paced Momentum Stock Ayr Wellness Inc. (AYRWF) Is Still Trading at a Bargain

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Ayr Wellness Inc. (AYRWF) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of 71.11% and 5.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Miromatrix Medical Inc. (MIRO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Miromatrix Medical Inc. (MIRO) delivered earnings and revenue surprises of 2.94% and 20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -30.77% and 1.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ICU Medical (ICUI) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of 26.09% and 2.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

QuidelOrtho (QDEL) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

QuidelOrtho (QDEL) delivered earnings and revenue surprises of 28.57% and 0.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ayr Wellness Inc. (AYRWF) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of 48% and 5.99%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Quanterix Corporation (QTRX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 5.66% and 1.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AdaptHealth Corp. (AHCO) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -96.77% and 0.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 14.89% and 4.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

PetIQ (PETQ) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

PetIQ (PETQ) delivered earnings and revenue surprises of 150% and 2.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Medtronic (MDT) Q1 Earnings Expected to Decline

by Zacks Equity Research

Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should You Buy Ayr Wellness (AYRWF) Ahead of Earnings?

by Zacks Equity Research

Ayr Wellness (AYRWF) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Homology Medicines (FIXX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Homology Medicines (FIXX) delivered earnings and revenue surprises of 10.53% and 23.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Prometheus Biosciences, Inc. (RXDX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 6.52% and 81.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Ayr Wellness Inc. (AYRWF) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.